Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 8, Issue 4, Pages 481-491
Publisher
Informa UK Limited
Online
2015-06-13
DOI
10.1586/17474086.2015.1053866
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
- (2015) Jahangir Abdi et al. Oncotarget
- Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
- (2015) Athalia R Pyzer et al. Human Vaccines & Immunotherapeutics
- Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection
- (2014) Benjamin W. Teh et al. BLOOD REVIEWS
- Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
- (2014) Balaji Balasa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
- (2013) G. T. Gorgun et al. BLOOD
- Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM)
- (2013) Sylvia Feyler et al. BLOOD REVIEWS
- Management of older adults with multiple myeloma
- (2013) Antonio Palumbo et al. BLOOD REVIEWS
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
- (2013) J. Rosenblatt et al. CLINICAL CANCER RESEARCH
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
- (2013) André Veillette et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Immunologic microenvironment and personalized treatment in multiple myeloma
- (2013) Marco Rossi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
- (2013) S. Bringhen et al. HAEMATOLOGICA
- Fact or fiction - identifying the elusive multiple myeloma stem cell
- (2013) Joshua Kellner et al. Journal of Hematology & Oncology
- The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide
- (2013) Tzu-Fei Wang et al. LEUKEMIA & LYMPHOMA
- Have drug combinations supplanted stem cell transplantation in myeloma?
- (2012) A. Palumbo et al. BLOOD
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
- (2012) Ivetta Danylesko et al. Clinical & Developmental Immunology
- Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes
- (2012) Sergio Rutella et al. Clinical & Developmental Immunology
- Novel lenalidomide-based combinations for treatment of multiple myeloma
- (2012) Mauro Cives et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma
- (2012) Don M. Benson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
- (2012) Giuseppina Bonanno et al. Journal of Translational Medicine
- The role of natural killer cells in immunity against multiple myeloma
- (2012) James Godfrey et al. LEUKEMIA & LYMPHOMA
- European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses
- (2012) H. Ludwig et al. ONCOLOGIST
- Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
- (2011) William H.D. Hallett et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Multiple myeloma – current issues and controversies
- (2010) Shaji Kumar CANCER TREATMENT REVIEWS
- SLAM-Family Receptors: Immune Regulators with or without SAP-Family Adaptors
- (2010) A. Veillette Cold Spring Harbor Perspectives in Biology
- Novel Immunotherapies
- (2009) Qing Yi CANCER JOURNAL
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function
- (2009) Mario-Ernesto Cruz-Munoz et al. NATURE IMMUNOLOGY
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
- (2008) O. Murillo et al. CLINICAL CANCER RESEARCH
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More